🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesHas anyone dealt with blood pressure went from scary to perfect - anyone else?? Page 4

Has anyone dealt with blood pressure went from scary to perfect - anyone else??

sophie_paris Thu, Oct 31, 2024 at 3:24 AM 39 replies 2,318 viewsPage 4 of 8
traveltech_sara
Member
156
678
Jan 2025
Remote, USA
Nov 12, 2024 at 3:28 PM#16

Adding the clinical framing, because it changes how the question reads.

Continuous metabolic monitoring dashboard for cardiovascular risk — I track everything in a spreadsheet and here's the month-over-month trend for my key markers:

Weight: consistent downtrend, -2.0 lbs/week average
Fasting glucose (finger stick): stable at 85 mg/dL
Blood pressure (home): 115/75 average
Resting heart rate: 65 bpm (down from 81)
Waist circumference: down 15 inches total

The resting heart rate improvement correlates with cardiovascular fitness gains. Everything is moving in the right direction.

Last edited: Nov 12, 2024 at 6:28 PM
11 9MeganSA_TX, LarryQC_SD, wanda_boise and 8 others
Reply Quote Save Share Report
carlos_SATX
Member
245
1,123
Oct 2024
San Antonio, TX
Nov 14, 2024 at 7:20 AM#17
traveltech_sara said:
Continuous metabolic monitoring dashboard for cardiovascular risk — I track everything in a spreadsheet and here's the month-over-month trend for my…

Same pattern here, and in the same order.

12 10FranDenver, Dr.BariatricHTX, LindaRN_retired and 9 others
Reply Quote Save Share Report
jim_asheville
Member
289
1,234
Aug 2024
Asheville, NC
Nov 15, 2024 at 11:13 PM#18
traveltech_sara said:
Continuous metabolic monitoring dashboard for cardiovascular risk — I track everything in a spreadsheet and here's the month-over-month trend for my…

NNT calculation for cardiovascular risk clinical endpoints: NNT = 1/ARR (absolute risk reduction).

From SELECT trial: MACE at 39 months — 6.5% semaglutide vs 8.0% placebo. ARR = 1.5%. NNT = 67 over 3.3 years.

Compare to established therapies:

InterventionNNTTimeframe
Semaglutide (MACE)673.3 years
Statins primary prevention (MI)~1005 years
Aspirin secondary prevention~772 years

These NNTs are clinically meaningful and comparable to accepted cardiovascular interventions.

13 11NurseAsh_DET, BenResearch_OR, MikeKY_noInsulin and 10 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
Dr.PathRoch
Member
456
2,123
Jun 2024
Rochester, MN
Nov 17, 2024 at 3:07 PM#19
traveltech_sara said:
Continuous metabolic monitoring dashboard for cardiovascular risk — I track everything in a spreadsheet and here's the month-over-month trend for my…

Lp(a) and cardiovascular risk: a nuance that matters. Unlike most lipid markers, Lp(a) is 90%+ genetically determined and doesn't really change with weight loss or GLP-1 therapy.

My Lp(a) has remained at 51 nmol/L across all time points. If yours is elevated (>50 nmol/L), you need additional risk mitigation strategies regardless of your GLP-1 response. Don't assume your medication is covering all cardiovascular risk factors.

Last edited: Nov 17, 2024 at 9:07 PM
14 12SaraMom3, Dr.MetabolicMD, RetaRick_CA and 11 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Nov 19, 2024 at 7:02 AM#20

Moderator note: good thread. Keeping it here rather than moving it, because the question is general enough to be useful. Tagging this one for the weekly digest.

36 9PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 33 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register